GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: This is an orally bioactive small molecule inhibitor of IL-17A interaction with its receptor and IL-17-mediated inflammation [1]. It is one of the compounds that are claimed in Dice Therapeutics' development pipeline. There are two named leads in their pipeline (DC-806 and DC-853 [2]) and a third unnamed lead, but as of May 2025 no name to structure(s) have been formally disclosed for these. DC-806 and DC-853 are both in phase 2 studies for plaque psoriasis.
|
|
Immunopharmacology Comments |
Inhibition of IL-17A signalling is a mechanism that is proposed for the treatment of IL-17-mediated chronic immunology indications. This small molecule binds the cytokine and prevents its interaction with the IL-17 receptor. |